By targeting a specific protein, Ohio State researchers hope to provide more effective treatments for patients with hard-to-cure cancers. Researchers at the OSUCCC &ndash; James have developed a drug that acts as an inhibitor for PRMT5, a protein that is over-expressed in many aggressive cancers, including lung cancer, triple-negative breast cancer, acute myeloid leukemia and glioblastoma. The team is currently conducting a clinical trial that uses the drug to target PRMT5, which is only present in cancer cells. &ldquo;It&rsquo;s a real exciting target because it&rsquo;s not expressed in normal human tissues, only in cancer cells. So the toxicity profile can be really well controlled,&rdquo; says Robert Baiocchi, MD, PhD.